001     167785
005     20240229133548.0
024 7 _ |a 10.1093/ajcn/nqaa422
|2 doi
024 7 _ |a pmid:33668069
|2 pmid
024 7 _ |a 0002-9165
|2 ISSN
024 7 _ |a 0095-9871
|2 ISSN
024 7 _ |a 1938-3207
|2 ISSN
024 7 _ |a 1938-3215
|2 ISSN
024 7 _ |a altmetric:101408709
|2 altmetric
037 _ _ |a DKFZ-2021-00547
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Koole, Janna L
|b 0
245 _ _ |a Circulating B-vitamin biomarkers and B-vitamin supplement use in relation to quality of life in patients with colorectal cancer: results from the FOCUS consortium.
260 _ _ |a Oxford
|c 2021
|b Oxford University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1625050487_23645
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 113(6):1468-1481
520 _ _ |a B vitamins have been associated with the risk and progression of colorectal cancer (CRC), given their central roles in nucleotide synthesis and methylation, yet their association with quality of life in established CRC is unclear.To investigate whether quality of life 6 months postdiagnosis is associated with: 1) circulating concentrations of B vitamins and related biomarkers 6 months postdiagnosis; 2) changes in these concentrations between diagnosis and 6 months postdiagnosis; 3) B-vitamin supplement use 6 months postdiagnosis; and 4) changes in B-vitamin supplement use between diagnosis and 6 months postdiagnosis.We included 1676 newly diagnosed stage I-III CRC patients from 3 prospective European cohorts. Circulating concentrations of 9 biomarkers related to the B vitamins folate, riboflavin, vitamin B6, and cobalamin were measured at diagnosis and 6 months postdiagnosis. Information on dietary supplement use was collected at both time points. Health-related quality of life (global quality of life, functioning scales, and fatigue) was assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 6 months postdiagnosis. Confounder-adjusted linear regression analyses were performed, adjusted for multiple testing.Higher pyridoxal 5'-phosphate (PLP) was cross-sectionally associated with better physical, role, and social functioning, as well as reduced fatigue, 6 months postdiagnosis. Associations were observed for a doubling in the hydroxykynurenine ratio [3-hydroxykynurenine: (kynurenic acid + xanthurenic acid + 3-hydroxyanthranilic acid + anthranilic acid); an inverse marker of vitamin B6] and both reduced global quality of life (β = -3.62; 95% CI: -5.88, -1.36) and worse physical functioning (β = -5.01; 95% CI: -7.09, -2.94). Dose-response relations were observed for PLP and quality of life. No associations were observed for changes in biomarker concentrations between diagnosis and 6 months. Participants who stopped using B-vitamin supplements after diagnosis reported higher fatigue than nonusers.Higher vitamin B6 status was associated with better quality of life, yet limited associations were observed for the use of B-vitamin supplements. Vitamin B6 needs further study to clarify its role in relation to quality of life.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|x 0
|f POF IV
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a B vitamins
|2 Other
650 _ 7 |a biomarkers
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a dietary supplement use
|2 Other
650 _ 7 |a fatigue
|2 Other
650 _ 7 |a folates
|2 Other
650 _ 7 |a functioning
|2 Other
650 _ 7 |a health-related quality of life
|2 Other
650 _ 7 |a pyridoxal 5′-phosphate
|2 Other
650 _ 7 |a vitamin B6
|2 Other
700 1 _ |a Bours, Martijn J L
|b 1
700 1 _ |a Geijsen, Anne J M R
|b 2
700 1 _ |a Gigic, Biljana
|b 3
700 1 _ |a Ulvik, Arve
|b 4
700 1 _ |a Kok, Dieuwertje E
|b 5
700 1 _ |a Brezina, Stefanie
|b 6
700 1 _ |a Ose, Jennifer
|b 7
700 1 _ |a Baierl, Andreas
|b 8
700 1 _ |a Böhm, Jürgen
|b 9
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 10
|u dkfz
700 1 _ |a Breukink, Stéphanie O
|b 11
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 12
|u dkfz
700 1 _ |a van Duijnhoven, Fränzel J B
|b 13
700 1 _ |a van Duijvendijk, Peter
|b 14
700 1 _ |a Gumpenberger, Tanja
|b 15
700 1 _ |a Habermann, Nina
|b 16
700 1 _ |a van Halteren, Henk K
|b 17
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 18
|u dkfz
700 1 _ |a Holowatyj, Andreana N
|b 19
700 1 _ |a Janssen-Heijnen, Maryska L G
|b 20
700 1 _ |a Keulen, Eric T P
|b 21
700 1 _ |a Kiblawi, Rama
|b 22
700 1 _ |a Kruyt, Flip M
|b 23
700 1 _ |a Li, Christopher I
|b 24
700 1 _ |a Lin, Tengda
|b 25
700 1 _ |a Midttun, Øivind
|b 26
700 1 _ |a Peoples, Anita R
|b 27
700 1 _ |a van Roekel, Eline H
|b 28
700 1 _ |a Schneider, Martin A
|b 29
700 1 _ |a Schrotz-King, Petra
|0 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
|b 30
|u dkfz
700 1 _ |a Ulrich, Alexis B
|b 31
700 1 _ |a Vickers, Kathy
|b 32
700 1 _ |a Wesselink, Evertine
|b 33
700 1 _ |a de Wilt, Johannes H W
|b 34
700 1 _ |a Gsur, Andrea
|b 35
700 1 _ |a Ueland, Per M
|b 36
700 1 _ |a Ulrich, Cornelia M
|b 37
700 1 _ |a Kampman, Ellen
|b 38
700 1 _ |a Weijenberg, Matty P
|b 39
773 _ _ |a 10.1093/ajcn/nqaa422
|g p. nqaa422
|0 PERI:(DE-600)1496439-9
|n 6
|p 1468-1481
|t The American journal of clinical nutrition
|v 113
|y 2021
|x 1938-3207
909 C O |o oai:inrepo02.dkfz.de:167785
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 30
|6 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-02
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AM J CLIN NUTR : 2019
|d 2021-02-02
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b AM J CLIN NUTR : 2019
|d 2021-02-02
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 2
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21